Sandoz says Amgen ‘dragging the chain’ in fight over bone drug biosimilar

Intellectual Property 2025-05-15 11:06 pm | Melbourne
Sandoz has accused Amgen of ‘dragging the chain’ as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.
For information on rights and reprints, contact subscriptions@lawyerly.com.au